by Sermonix Pharmaceuticals | Jul 18, 2024 | News
New intellectual property significantly broadens potential patient population for lasofoxifene, which previously demonstrated antitumor activity in breast cancers with ESR1 mutations COLUMBUS, Ohio, July 18, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc.,...
by Sermonix Pharmaceuticals | Jun 12, 2024 | News
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumors Phase 3 ELAINE-3 study is currently investigating lasofoxifene as a potential therapy for ESR1-mutated breast cancer COLUMBUS,...
by Sermonix Pharmaceuticals | Jun 6, 2024 | News
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in China Under strategic collaboration agreement signed in January, Henlius received exclusive rights from Sermonix...
by Sermonix Pharmaceuticals | Apr 29, 2024 | News
‘Significant and clinically meaningful’ results support Sermonix’s plans to study oral lasofoxifene’s impact on VVA in women with mBC being treated in ELAINE-3 trial COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Apr 22, 2024 | News
COLUMBUS, Ohio, Apr. 22, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a...
Recent Comments